Les bloqueurs du système rénine-angiotensine-aldostérone en temps de pandémie Covid-19 : amis ou ennemis ? [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?]
Fiche du document
13 mai 2020
- handle: 10670/1.3qyery
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32401442
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C2FECE47276D6
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
A. Pechère-Bertschi et al., « Les bloqueurs du système rénine-angiotensine-aldostérone en temps de pandémie Covid-19 : amis ou ennemis ? [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?] », Serveur académique Lausannois, ID : 10670/1.3qyery
Métriques
Partage / Export
Résumé
ACE2 is not only an enzyme that counters the effects of the renin-angiotensin-aldosterone system (RAAS) but is also the entry receptor for SARS-CoV-2, the virus of the Covid-19 pandemic. Some experimental data suggest that ACE inhibitors and ARBs increase ACE2 levels, thus raising concerns on their security in Covid-19 positive patients. However, some studies have shown protection by these drugs in lower tract respiratory infections and ARDS. The actual consensus is to continue the treatment with RAAS inhibitors, abrupt withdrawal, especially in patients with cardiac or renal conditions, being hazardous in terms of cardiovascular outcomes, except in patients hospitalized in intensive care with hemodynamic instability. This position statement is actually unanimous among all international learned societies.